阿托伐他汀对急性冠脉综合征患者血清CD40L和MMP9水平影响.docVIP

阿托伐他汀对急性冠脉综合征患者血清CD40L和MMP9水平影响 　　【摘要】目的：观察阿托伐他汀对急性冠脉综合征(acute coronary syndrome，ACS)患者血清白细胞分化抗原配体40(CD40L)和基质金属蛋白酶-9(MMP-9)水平的影响。方法：将67例ACS患者随机分为他汀治疗组35例(阿托伐他汀20 mg/d)和非他汀治疗组32例。分别于发病24 h内和治疗7 d后测定血清CD40L和MMP-9水平；选取同期健康查体者35例为对照组。结果：治疗前ACS患者血清CD40L和MMP-9水平均较对照组高(P0.01)；ACS患者治疗7 d后CD40L和MMP-9水平均较治疗前降低，且他汀治疗组两者降低程度明显高于非他汀治疗组，差异均有统计学意义(P0.05)；ACS患者血浆CD40L和MMP-9之间成正相关(r=0.52，P0.001)。结论：ACS患者血清CD40L和MMP-9水平增高，血清CD40L与MMP-9之间成正相关；阿托伐他汀可以降低ACS患者血清CD40L和MMP-9表达，减少冠状动脉粥样斑块炎症反应和基质成分降解，具有稳定斑块作用；ACS患者早期应用他汀类强化治疗可能对患者的治疗效果更好，对进一步预防ACS患者的心脏缺血事件有积极作用。 　　【关键词】急性冠脉综合征；白细胞分化抗原配体40；基质金属蛋白酶-9；阿托伐他汀 　　 　　The Impact of Atorvastatin on Serum CD40L and MMP-9 Levels of Patients with Acute Coronary Syndrome/WANG A-lan，DING Xiao-hua，HUANG Hui-yan.//Medical Innovation of China，2012，9(11)：010-012 　　【Abstract】Objective：To observe impact of atorvastatin on leukocyte differentiation antigen ligand 40(CD40L) and matrix metalloproteinase-9(MMP-9) levels of patients with acute coronary syndrome.Methods：67 patients with ACS were randomly divided into statin treatment group(35 cases，atorvastatin，20 mg/d) and non-statin treatment group(32 cases).Serum CD40L and MMP-9 levels were measured within 48 hours after onset and in 7 days after treatment，respectively.Control group were 35 healthy people over the same period.Results：Before treatment，serum CD40L and MMP-9 levels of patients with ACS were higher than those of control group(P0.01). 7 days after treatment，CD40L and MMP-9 levels of ACS patients decreased，and statin treatment group reduced significantly higher than non-statin treatment group，the differences were statistically significant (p0.05).CD40L and MMP-9 were positive correlation in ACS patients (r=0.52，P0.001).Conclusion：Levels of CD40L and MMP-9 in ACS patients increase， CD40L and MMP-9 are positive correlation.Atorvastatin can reduce the expression of serum CD40L and MMP-9 in patients with ACS，and reduced coronary plaque inflammation and matrix component degradation，it can stable plaque